Corcept Therapeutics Incorporated (CORT) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Corcept Therapeutics Incorporated stock (CORT) is currently trading at $40.47. Corcept Therapeutics Incorporated PE ratio is 41.24. Corcept Therapeutics Incorporated PS ratio (Price-to-Sales) is 4.72. Analyst consensus price target for CORT is $65.40. WallStSmart rates CORT as Underperform.
- CORT PE ratio analysis and historical PE chart
- CORT PS ratio (Price-to-Sales) history and trend
- CORT intrinsic value — DCF, Graham Number, EPV models
- CORT stock price prediction 2025 2026 2027 2028 2029 2030
- CORT fair value vs current price
- CORT insider transactions and insider buying
- Is CORT undervalued or overvalued?
- Corcept Therapeutics Incorporated financial analysis — revenue, earnings, cash flow
- CORT Piotroski F-Score and Altman Z-Score
- CORT analyst price target and Smart Rating
Corcept Therapeutics Incorporated
📊 No data available
Try selecting a different time range
CORT Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Corcept Therapeutics Incorporated (CORT)
CORT trades 632% above its Graham fair value of $5.58, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Corcept Therapeutics Incorporated (CORT) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in peg ratio, institutional own.. Concerns around operating margin and price/book. Fundamentals are solid but monitor weak areas for improvement.
Corcept Therapeutics Incorporated (CORT) Key Strengths (4)
Growing significantly faster than its price suggests
73.02% of shares held by major funds and institutions
Mid-cap company balancing growth potential with stability
Solid profitability: $15 profit per $100 equity
Supporting Valuation Data
Corcept Therapeutics Incorporated (CORT) Areas to Watch (6)
Earnings declining -21.60%, profits shrinking
Near-zero operating margins, business under pressure
Very expensive at 5.7x book value
Premium valuation at 4.7x annual revenue
Solid revenue growth at 11.10% per year
Decent profitability, keeps $13 per $100 revenue
Supporting Valuation Data
Corcept Therapeutics Incorporated (CORT) Detailed Analysis Report
Overall Assessment
This company scores 50/100 in our Smart Analysis, earning a C- grade. Out of 10 metrics analyzed, 4 register as strengths (avg 8.5/10) while 6 fall into concern territory (avg 3.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on PEG Ratio, Institutional Own., Market Cap. Valuation metrics including PEG Ratio (0.81) suggest the stock is attractively priced. Profitability is solid with Return on Equity at 15.00%.
The Bear Case
The primary concerns are EPS Growth, Operating Margin, Price/Book. Some valuation metrics including Price/Sales (4.72), Price/Book (5.69) suggest expensive pricing. Growth concerns include Revenue Growth at 11.10%, EPS Growth at -21.60%, which may limit upside. Profitability pressure is visible in Operating Margin at 2.22%, Profit Margin at 13.10%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether EPS Growth improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 15.00% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 11.10% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (PEG Ratio, Institutional Own.) and negatives (EPS Growth, Operating Margin). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
CORT Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
CORT's Price-to-Sales ratio of 4.72x trades at a deep discount to its historical average of 310.95x (5th percentile). The current valuation is 100% below its historical high of 9285.56x set in Jan 2010, and 27% above its historical low of 3.73x in Mar 2020.
WallStSmart Analysis Synopsis
Data-driven financial summary for Corcept Therapeutics Incorporated (CORT) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Corcept Therapeutics Incorporated operates as a stable business with moderate growth and solid fundamentals. Revenue reached 761M with 11% growth year-over-year. Profit margins of 13.1% are healthy, with room for further expansion as the business scales.
Key Findings
ROE of 1500.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Generating 38M in free cash flow and 38M in operating cash flow. Earnings are translating into actual cash generation.
What to Watch Next
Margin expansion: can Corcept Therapeutics Incorporated push profit margins above 15% as the business scales?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Corcept Therapeutics Incorporated.
Bottom Line
Corcept Therapeutics Incorporated offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Corcept Therapeutics Incorporated(CORT)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Corcept Therapeutics Incorporated discovers, develops, and markets drugs for the treatment of severe metabolic, cancer, and psychiatric disorders in the United States. The company is headquartered in Menlo Park, California.